EIE. S. Ilyina

E. S. Ilyina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


E. S. Ilyina has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Subacute sclerosing panencephalitis in children: series of clinical case reports

    by R.TS. Bembeyeva, E.L. Usacheva, S.V. Piliya, E.S. Ilyina, A.K. Shakaryan, A.S. Kozlovskiy, L.M. Kolpakchi, A.A. Kozyreva, I.D. Fedonyuk

    Subacute sclerosing panencephalitis (SSPE) is a rare complication caused by persistent measles infection and characterized by a decline in cognitive functions and severe motor impairments. Since SSPE is considered a potentially fatal complication of acute measles infection and is typically develops in young individuals especially those infected prior to the age of two years old, special attention must be paid to the implementation of vaccination programs that can prevent severe disease. Thus, the purpose of this research was to present the demographic and clinical characteristics of pediatric patients with SSPE in order to enhance its early diagnosis and to raise the pediatricians' awareness of this serious measles complication. In this series of case reports Authors represent the clinical picture, laboratory and instrumental data of six children with SSPE admitted at the Russian Children's Clinical Hospital with the Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia (Moscow, Russia) in Aug. 2022-Aug. 2024. Authors have conducted an analysis of complaints, clinical symptoms, laboratory, neurophysiological and neuroimaging data of 6 patients with SSPE. All patients have undergone cerebrospinal fluid (CSF) analysis, magnetic resonance imaging (MRI) of the brain and video EEG monitoring during both wakefulness and sleep at the time of diagnosis. Currently, there is no specific treatment for SSPE that would either lead to symptom regression or prevent the related disability. Therefore, vaccination remains the only effective means for the SSPE prevention.

  • CLINICAL MANIFESTATIONS OF ANTI-NMDA RECEPTOR ENCEPHALITIS IN CHILDREN

    by R.Ts. Bembeeva, U.M. Azizova, N.N. Zavadenko, E.S. Ilyina, A.A. Kholin, A.K. Shakaryan, S.V. Piliya, I.V. Mitrofanova, Yu.A. Kursakova, I.D. Fedonyuk, et al.

    The aim of the study was to determine the clinical features of anti-NMDAR encephalitis in children. Materials and methods of research: 11 patients were selected from the group of children with autoimmune encephalitis, who met the diagnostic criteria for reliable anti-NMDAR encephalitis. A retro-prospective analysis of clinical symptoms, laboratory, neurophysiological and neuroimaging data, treatment, duration of primary hospitalization and long-term results of treatment was carried out, neuropsychological testing of patients was performed in the follow-up. Results: the age of the patients was 8.5±4.4 years, the gender composition of boys/girls was 1/10 (9.1%/90.9%). The average follow-up period was 17±12 months. In 73% of cases, there was an acute onset of the disease without a prodromal phase and with rapidly growing signs of neurological dysfunction: behavior change (11/100%), epileptic seizures (11/100%), speech impairment (10/90.9%), movement disorders (10/90.9%), disturbed sleep/wakefulness rhythm (9/81.8%), hallucinations (5/45.5%), autonomic disorders (6/54.5%), sensory disturbance (1/9,1%). In 82% of cases, therapy was required in the intensive care unit. When analyzing EEG monitoring in children, the extreme delta brush pattern was revealed in only one patient. Neuroimaging revealed no specific changes in the substance of the brain. The paraneoplastic nature of the disease could not be established in any case. 4 patients (36.36%) had relapses of the disease after 1.5–27 months. from the onset of the disease. All children showed a favorable outcome without a gross neurological deficit, but complaints of increased fatigue, headaches, poor memory, a decrease in vocabulary, and impulsive behavior persisted.

  • Open Access

    Retrospective analysis of the natural history of type 1 spinal muscular atrophy in children

    by D. V. Vlodavets, N. V. Ganina, Е. С. Ильина, A. A. Kokorina, L. M. Kuzenkova, E. Yu. Sapego, D. S. Smirnov, Yu. A. Shevtsova, A. V. Saulina, A. N. Petrov, et al.

    Objective. To analyze the natural course of type 1 spinal muscular atrophy in children with the onset of the disease up to 6 months in the Russian population.Material and methods. The retrospective multicenter study included data of 54 children with an established diagnosis of type 1 spinal muscular atrophy who did not receive therapy with nusinersen, risdiplam, branaplam, onasemogen abeparvovec-xioi, or other anti-sense oligonucleotides / selective SMN2 splicing modifiers or genetherapy drugs for SMN1 genetransduction. Basedon medical records, the scientists have collected all available information on the health status of children, the need for respiratory support and death or start of long-term mechanical ventilation.Results. The median time from birth to the onset of the combined event (death or initiation of long-term respiratory support), determined using the Kaplan-Meier method, was 365 [269; 409] days (12 months). The date of death was known in 22 out of 54 children. The median age of death was 301,5 [181; 375] days (9,9 months). The initiation date of long-term respiratory support was known in 15 of 54 patients, the median was 180 [91; 276] days (5,9 months). Both the start date of long-term respiratory support and the date of death were known in 5 of 54 children; whileit was found that the median time from the initiation of long-term respiratory support to death in these children was 361 [135; 619] day (11,87 months).In a subgroup of 32 children with available date of initiation of long-term respiratory support and / or the date of death, the median time from birth to the combined event was 245,5 [173; 331] days (8,07 months).Conclusion. In the course of a retrospective study, the authors obtained the information on the date of the onset of constant respiratory support and the date of death from the date of birth in the absence of pathogenetic treatment in children with type 1 spinal muscular atrophy. The data obtained in the Russian population are comparable with the published international data. This information can be useful for additional assessment of the health status of patients who received drugs affecting the level of SMN protein in the body, as well as reference data for the development of new approaches to therapy.


  • Open Access

    The efficacy and safety of nusinersen within the expanded access program in Russia

    by S. B. Artemieva, L. M. Kuzenkova, E. S. Ilyina, Yu. A. Kursakova, L. M. Kolpakchi, E. Yu. Sapego, A. A. Golenko, S. G. Popovich, D. V. Parshin, O. A. Shidlovskaya, et al.

    Introduction. Spinal muscular atrophy is a severe neuromuscular disease characterized by rapid progression of muscle weakness and early death. Pathogenetic therapy with nusinersen can significantly change the course of the disease and enable the patient to acquire new skills. The study of the efficacy and safety of nusinersen therapy in patients with type 1 spinal muscular atrophy should be continued. The aim of the study was to assess the safety and efficacy of nusinersen therapy in patients with type 1 spinal muscular atrophy for 6 months as part of an expanded access program at federal and regional healthcare facilities. Materials and methods. Patients with type 1 spinal muscular atrophy received nusinersen therapy under the expanded access program (NCT02865109). Patients were evaluated before starting treatment and 6 months after starting treatment. Overall motor development and motor function was assessed using the Hammersmith Infant Neurological Status Scale Part 2 and the Philadelphia Pediatric Hospital Neonatal Motor Scale. Results. 41 children aged 6 to 38 months received nusinersen therapy between July 2019 and March 2020. At the time of analysis, all patients were alive and continued treatment. The average improvement on the Hammersmith Hospital Neurological Status Scale was 3.7 points after 6 months of therapy compared to baseline (n = 39, p 0.001). The mean improvement on the Children’s Hospital of Philadelphia Scale for the Diagnosis of Motor Function in Newborns was 9.8 after 6 months of therapy from baseline (n = 30, p 0.001). Conclusion. The efficacy and safety of nusinersen have been demonstrated in real clinical practice in Russia in the treatment of early-onset spinal muscular atrophy.


  • Open Access

    Movement Disorders in the Structure of the Different Mental Processes Types in Child with Opsoclonus-Myoclonus Syndrome

    by Y.N. Fedorova, Y.V. Mikadze, N.S. Burlakova, E.S. Ilyina

    Opsoclonus-myoclonus syndrome (OMS) is a rare and often relapsing neurologic illness with onset in early childhood. Patients with OMS have longitudinal mental development disturbances and features of emotional and behavioral state. Interruption of the normative mental development is determined by movement disorders (primary defect), which establish new conditions for child's life for a long time. Case study of the child with OMS and the discussion of movement disorders in the structure of the different mental processes types in this disease are presented. Movement disorders (primary defect) and their effects (secondary and other defects) affecting mental development are discussed (based on the levels of movements coordination concept by N.A. Bernstein). The research detects mistmatch between levels of movements coordination (intactness of higher levels and disturbance of lower levels), which important for prospective analysis of the mental disorders mechanisms in children with OMS.


  • Open Access

    Xenon in the treatment of super-refractory status epilepticus. Case report

    by Vladimir V. Lazarev, B. I. Golubev, G. P. Brusov, L. E. Tsypin, E. S. Ilina, A. A. Holin, E. L. Usacheva

    Tolerance to specific drug therapy may occur in the relief of epileptic status. One of the solutions this problem are use of volatile anesthetics, which have a number of negative properties in addition to positive effects. In the presented description of a clinical case of a super-refractory status epilepticus in a 5-year-old child, xenon, possessing the properties of a general anesthetic and having no negative side effects, was successfully used to relieve seizures. By inhalation of the xenon-oxygen mixture in the proportion of 60–70 % xenon and 30–40 % oxygen, it was possible to completely level the convulsive activity of the patient during the procedure, which was confirmed by electroencephalogram. The presented case gives grounds for further study of the possibility of using xenon in the treatment of super-refractory status epilepticus in children.


  • OPSOCLONUS–MYOCLONUS SYNDROME IN CHILDREN WITH NEUROGENIC TUMORS: A VIEW OF A NEUROLOGIST

    by Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology, O.B. Malevich, E.S. Il’iNa, Moscow Russian Children'S Clinical Hospital Of The Ministry Of Healthcare Of Russia, S.P. Homyakova, D.Y. Kachanov, T.V. Shamanskaya, M.E. Lochmatova, S.R. Varfolomeeva

    Облако Mail.Ru - это ваше персональное надежное хранилище в интернете. Все нужные файлы всегда под рукой, доступны в любой точке мира с компьютера или смартфона.